KRAS and cancer: CDK9 inhibitory activity was experimentally confirmed using LS513 (KRAS G12D), SW620 (KRAS G12V), and Colo320 (RAS WT) tumor cell line models, and demonstrated the effectiveness of this group of molecules in treating cancer harboring KRAS mutations [121].